Clinical trial
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00005609 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005609 |
|---|---|
| Title | Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | Rituximab for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated or Previously Treated Patients |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Start date | Apr 1, 2000 |
| Completion | Feb 1, 2004 |
| First posted | Feb 16, 2004 |
| Last update posted | Aug 16, 2013 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: